Ratings i-SENS, Inc.

Equities

A099190

KR7099190001

End-of-day quote Korea S.E. Other stock markets 23:00:00 07/05/2024 BST			5-day change	1st Jan Change
19,660 ^KRW	+0.82%		+0.15%	-31.26%

04-30	I-SENS, Inc. announced that it has received KRW 50 billion in funding from NH Investment & Securities Co., Ltd., Atinum Investment Co., Ltd	CI
04-26	I-SENS, Inc. announced that it expects to receive KRW 50 billion in funding from NH Investment & Securities Co., Ltd., Atinum Investment Co., Ltd	CI

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 55% by 2026.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
I-SENS, INC.	-31.26%	397M	-
SHOCKWAVE MEDICAL, INC.	+73.50%	12.41B	B-
PENUMBRA, INC.	-19.26%	8.14B	C+
MASIMO CORPORATION	+2.40%	7.2B	C-
GETINGE AB	+3.66%	5.93B	B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+11.89%	5.43B	D+
APT MEDICAL INC.	+37.45%	4.89B	-
ASAHI INTECC CO., LTD.	-19.82%	4.09B	B-
INARI MEDICAL, INC.	-35.58%	2.49B	C
SKAN GROUP AG	+0.74%	2.04B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes